The dopamine hypothesis of schizophrenia: Current status, future prospects

International Clinical Psychopharmacology

Volumn 12, Issue 6, 1997, Pages 297-308

  Willner, P ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Dopamine; Dopamine receptors; Negative symptoms; Neuroleptic drugs; Positive symptoms; Prefrontal cortex; Schizophrenia

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT;

DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; DRUG RECEPTOR BINDING; FOREBRAIN; HUMAN; HYPOTHESIS; NEGATIVE SYNDROME; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 0031408442     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199711000-00002     Document Type: Review

References (86)

1. Aghajanian GK and Marek GJ (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology, 36, 589-599.
2. Alexander GE, De Long MR and Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Reviews of Neuroscience, 9, 357-381.
3. Allen RM and Young SJ (1978) Phencyclidine-induced psychosis. American Journal of Psychiatry, 135, 1081-1084.
4. Andreasen N, O'Leary D, Arndt S, Cizadlo T, Nopoulos P and Flaum M (1996) Neural substrates of frontal function in schizophrenia. In: Dopamine Disease States (Eds RJ Beninger, T Palomo and T Archer T), pp. 523-536. Editorial Cym, Madrid.
5. Angrist B, Peselow E, Rubinstein M, Wolkin A, Rotrosen J (1985) Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology, 85, 277-283.
6. Begic D and Stojanovic V (1995) Eye movements in schizophrenia. Psychiatria Danubina, 7,119-122.
7. Belmaker RH and Wald D (1977) Haloperidol in normals. British Journal of Psychiatry, 131, 222-223.
8. Bowers MB (1985) Cerebrospinal fluid homovanillic acid and hypokinetic effects of neuroleptics. Psychopharmacology, 85, 184-186.
9. Boyer P, Lecrubier Y and Puech AJ (1990) Treatment of positive and negative symptoms: pharmacologic approaches. In: Schizophrenia: Positive and Negative Symptoms and Syndromes. Modern Problems in Pharmacopsychiatry, vol 24 (Ed NC Andreasen), pp. 152-174. Karger, Basel.
10. Boyer P, Lecrubier Y, Puech AJ, Dewailly J and Aubin F (1995) Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry, 166, 68-72.
11. Braff DL, Stone C, Callaway E, Geyer M, Glick I and Ball L (1978) Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology, 15, 339-343.
12. Carlsson A and Lindqvist M (1963) Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica, 20, 140-144.
13. Carlsson M and Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson's disease. Trends in Neuroscience, 13, 272-276.
14. Carpenter WT, Heinrich DW and Wagman AJL (1988) Deficit and non deficit forms of schizoprenia: the concept. American Journal of Psychiatry, 145, 578-583.
15. Chouinard G and Jones BD (1980) Neuroleptic-induced supersensitivity psychosis: clinical and pharmacological characteristics. American Journal of Psychiatry, 137, 16-21.
16. Creese I (1987) Biochemical properties of CMS dopaminergic receptors. In: Psychopharmacology: The Third Generation of Progress (Ed MY Meltzer), pp. 257-264. Raven, New York.
17. Creese I, Burt DR and Snyder SH (1976) DA receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192, 481-483.
18. Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process. British Medical Journal, 280, 66-68.
19. Crow TJ (1996) The failure of the dopamine hypothesis and its consequences for the future direction of psychosis research. In: Dopamine Disease States (Eds RJ Beninger, T Palomo and T Archer), pp. 555-567. Editorial Cym, Madrid.
20. Crow TJ and Johnstone EC (1986) Schizophrenia: nature of the disease process and its biological correlates. In: Handbook of Physiology: The Nervous System (Eds VB Mountcastle and F Plum), pp. 843-869. American Physiological Society, Baltimore.
21. Daniel DG, Weinberger DR, Jones DW, Zigun JR, Coppola R, Handel S, Bigelow LB, Goldberg TE, Berman KF and Kleinman JE (1991) The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. Journal of Neuroscience, 11, 1907-1917.
22. Davidson M and Davis K (1988) A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Archives of General Pschiatry, 45, 561-563.
23. Davidson M, Keefe RSC, Mohs RC, Horvath TB and Davis KL (1986) L-dopa challenge and relapse in schizophrenia. American Journal of Psychiatry, 144, 1271-1276.
24. Davidson M, Losonczy MF, Mohs RC, Lesser JC, Powchik P, Freed LB, Davis BM, Mykytyn VV and Davis KL (1987) Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. Neuropsychopharmacology, 1, 17-23.
25. Davidson M, Harvey PD, Bergman RL, Powchik P, Kaminsky R, Losonczy MF and Davis KL (1990) Effects of the D1 agonist SKF 38393 combined with haloperidol in schizophrenic patients. Archives of General Psychiatry, 47, 190-191.
26. Davis KL, Kahn RS, Ko G and Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry, 148, 1474-1486.
27. Deakin JFW, Simpson MDC, Slater P and Hellewell JSE (1997) Familial and developmental abnormalities of frontal lobe function and neurochemistry in schizophrenia. Journal of Psychopharmacology, 11, 123-132.
28. Devenand DP, Bowers MB, Hoffman FJ and Nelson JC (1985) Elevated plasma homovanillic acid in depressed females with melancholia and psychosis. Psychiatry Research, 15, 1-4.
29. Drevets WC, Videen TO, Price JL, Preslorn SH, Carmichael ST and Raichle ME (1992) A functional anatomical study of unipolar depression. Journal of Neuroscience, 12, 2628-2641.
30. Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, Van Haaften AJ, Boom AJ, van Laarhoven JH and Busard HL (1993) Ritanserin, a selective 5HT2/1C antagonist and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. British Journal of Psychiatry, 163, 451-455.
31. Elsworth D, Leahy DJ, Roth RJ and Redmond DE (1987) Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates. Journal of Neural Transmission, 68, 51-62.
32. Farde L, Halldin C, Stone-Elander S and Sedvall G (1987) PET analysis of human dopamine receptors using 11C-SCH23390 and 11C-raclopride. Psychopharmacology, 92, 278-284.
33. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H and Sedvall G (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients: a positron emission tomography study with [11C]raclopride. Archives of General Psychiatry, 47, 213-219.
34. Farde L, Gustavsson JP and Jonsson E (1997) D2 dopamine receptors and personality traits. Nature, 385, 590.
35. Frith CD (1987) The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action. Psychological Medicine, 17, 631-648.
36. Galloway MP and Roth RH (1983) Biochemical response of dopamine neurons to atypical neuroleptics is not dependent on autoreceptors [Abstract]. Society for Neuroscience Abstracts, 9, 1003.
37. Grace AA and Bunney BS (1986) Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording. Journal of Pharmacology and Experimental Therapeutics, 238, 1092-1100.
38. Greenshaw AJ, Baker GB and Wishart TB (1991) Dopamine receptor changes during chronic drug administration. In: Psychoactive Drugs: Tolerance and Senstization (Eds AJ Goudie and MW Emmett-Oglesby), pp. 353-406. Humana, Clifton, New Jersey.
39. Groenewegen HK, Berendse HW, Meredith GE, Haber SN, Voorn P, Wolters JG and Lohman AHM (1991) Functional anatomy of the ventral, limbic system-innervated striatum. In: The Mesolimbic Dopamine System: From Motivation to Action (Eds P Willner and J Scheel-Kruger), pp. 19-59. Wiley, Chichester.
40. Hollister LE (1962) Drug-induced psychoses and schizophrenic reactions: a critical comparison. Annals of the New York Academy of Sciences, 96, 80-88.
41. Hyttel J, Larsen JJ, Christensen AV and Arnt J (1985) Receptor binding profiles of neuroleptics. Psychopharmacology, (suppl 2), 9-18.
42. Iversen SD (1995) Interactions between excitatory amino acids and dopamine systems in the forebrain: implications of schizophrenia and Parkinson's disease. Behavioural Pharmacology, 6, 478-491.
43. Jaskiw GE, Weinberger DR and Crawley JN (1991) Microinjection of apomorphine into the prefrontal cortex of the rat reduces dopamine metabolite concentrations in microdialysate from the caudate nucleus. Biological Psychiatry, 29, 703-706.
44. Johnstone EC, Crow TJ, Frith CD, Carney MWP and Price JC (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet, i, 848-851.
45. Kahn RS and Davis KL (1995) New developments in dopamine and schizophrenia. In: Psychopharmacology: The Fourth Generation of Progress (Eds FE Bloom and DJ Kupfer), pp. 1193-1203. Raven, New York.
46. Kane JM and Mayerhoff D (1989) Do negative symptoms respond to pharmacological treatment? British Journal of Psychiatry, 155 (suppl 7), 115-118.
47. Karlsson P, Smith L, Farde L, Harnryd C, Sedvall G and Wiesel FA (1995) Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology, 121, 309-316.
48. Kendler KS, Heninger GR and Roth RH (1982) Influence of dopamine agonists on plasma and brain levels of homovanillic acid. Life Sciences, 30, 2063-2069.
49. Kovelman JA and Scheibel AB (1984) A neurohistological correlate of schizophrenia. Biological Psychiatry, 19, 1601-1621.
50. Le Moal M (1995) Mesocorticolimbic dopaminergic neurons: functional and regulatory roles. In: Psychopharmacology: The Fourth Generation of Progress (Eds FE Bloom and DJ Kupfer), pp. 283-294. Raven, New York.
51. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T and Frackowiak RSJ (1992) Patterns of cerebral blood flow in schizophrenia. British Journal of Psychiatry, 160, 179-186.
52. Lipska BK, Jaskiw GE and Weinberger DR (1993) Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal hippocampal damage: a potential model of schizophrenia. European Neuropsychopharmacology, 3, 398.
53. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL and Weinberger DR (1995) Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology, 122, 35-43.
54. Losonczy MF, Davidson M and Davis KL (1987) The dopamine hypothesis of schizophrenia. In: Psychopharmacology: The Third Generation of Progress (Ed HY Meltzer), pp. 715-726. Raven, New York.
55. Louilot A, Le Moal M, Simon H (1989) Opposite influences of dopaminergic pathways to the prefrontal cortex or the septum on the dopaminergic transmission in the nucleus accumbens: an in vivo voltammetric study. Neuroscience, 29, 45-56.
56. Mansbach R and Geyer M (1989) Effects of phencyclidine and phencyclidine analogs on sensorimotor gating in the rat. Neuropsychopharmacology, 2, 299-308.
57. Mansbach R, Geyer M and Braff D (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology, 94, 507-514.
58. Martinot JL, Peron-Magnin P, Huret JD, Mazoyer B, Baron JC, Boulenger JP, Loc'h C, Maziere B, Caillard V and Loo H (1989) Striatal D2 dopaminergic receptors with positron emission tomography and 76Br-bromospiperone in untreated schizophrenic patients. American Journal of Psychiatry, 147, 44-50.
59. Meltzer HY (1995) Atypical antipsychotic drugs. In: Psychopharmacology: The Fourth Generation of Progress (Eds FE Bloom and DJ Kupfer), pp. 1277-1286. Raven Press, New York.
60. Memo M, Pizzi M, Nisoli E, Missale CM, Carruba MO and Spano P (1987) Repeated administration of (-)sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic regions. European Journal of Pharmacology, 138, 45-51.
61. Mogenson GJ and Yim CC (1991) Neurmodulatory functions of the mesolimbic dopamine system: electrophysiological and behavioural studies. In: The Mesolimbic Dopamine System: From Motivation to Action (Eds P Willner and J Scheel-Kruger), pp. 105-130. Wiley, Chichester.
62. Nestler EJ (1997) Schizophrenia: an emerging pathophysiology. Nature, 385, 578-579.
63. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Soeya Y, Sassa T, Sudo Y, Matsushima E, et al. (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature, 385, 634-636.
64. Perrault G, Depoortere R, Morel E, Sanger DJ and Scatton B (1997) Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Journal of Pharmacology and Experimental Therapeutics, 280, 73-82.
65. Robbins TW (1991) Cognitive deficits in schizophrenia and Parkinson's disease: neural basis and the role of dopamine. In The Mesolimbic Dopamine System: From Motivation to Action (Eds P Willner and J Scheel-Kruger), pp. 497-528. Wiley, Chichester.
66. Roth RH, Wolf ME and Deutch AY (1987) Neurochemistry of Midbrain dopamine neurons. In Psychopharmacology: The Third Generation of Progress (Ed HY Meltzer), pp. 81-94. Raven, New York.
67. Rupniak NMJ, Hall MD, Kelly E, Fleminger S, Kilpatrick G, Jenner P and Marsden CD (1985) Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs. Journal of Neural Transmission, 62, 249-266.
68. Sams-Dodd F (1996) Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behavioural Pharmacology, 7, 3-23.
69. Sawaguchi T and Goldman-Rakic PS (1991) D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science, 251, 947-950.
70. Schmajuk NA (1987) Animal models for schizophrenia: the hippocampally lesioned animal. Schizophrenia Bulletin, 13, 317-327.
71. Sedvall G and Farde L (1995) Chemical brain anatomy in schizophrenia. Lancet, 346, 743-749.
72. Seeman P (1995) Dopamine receptors: clinical correlates. In Psychopharmacology: The Fourth Generation of Progress (Eds FE Bloom and DJ Kupfer), pp. 295-302. Raven, New York.
73. 2A receptors in antipsychotic and anticataleptic action. Journal of Psychopahrmacology, 11, 15-17.
74. Serra G, Forgione A, D'Aquila PS, Collu M, Fratta W and Gessa GL (1990) Blockade of DA autoreceptors: possible mechanism of antidepressant action of L-sulpiride. In: Dopamine and Mental Depression (Eds GL Gessa and G Serra), pp. 185-191. Pergamon, Oxford.
75. Snyder SH (1973) Catecholamines in the brain as mediators of amphetamine psychosis. Archives of General Psychiatry, 27, 169-179.
76. Sanfilipo M, Wolkin A, Angrist B, van Kammen DP, Duncan E, Wieland S, Cooper TB, Peselow ED, Rotrosen J (1996) Amphetamine and negative symptoms of schizophrenia. Psychopharmacology, 123, 211-214.
77. Spano PF, Govoni S and Trabucchi M (1978) Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Advances in Biochemical Psychopharmacology, 19, 155-165.
78. Swerdlow NR, Lipska BK, Weinberger DR, Braff DL, Jaskiw GE and Geyer MA (1995) Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Psychopharmacology, 122, 27-34.
79. Tassin J-P, Herve D, Vezina P, Trovero F, Blanc G and Glowinsko G (1991) Relationships between mesocortical and mesolimbic dopamine neurons: functional correlates of D1 receptor heteroregulation. In The Mesolimbic Dopamine System: From Motivation to Action (Eds P Willner and J Scheel-Kruger), pp. 175-196. Wiley, Chichester.
80. Turner TH, Cookson JC, Wass JAH, Drury PL, Price PA, Besser GM (1984) Psychotic reactions during treatment of pituitary tumours with dopamine agonists. British Medical Journal, 289, 1101-1103.
81. Weinberger DR, Berman KF and Illowsky BP (1988) Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence of a monoaminergic mechanism. Archives of General Psychiatry, 45, 609-615.
82. Wetzel H, Hillert A, Grunder G and Benkert O (1992) Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenia. American Journal of Psychiatry, 151, 1499-1502.
83. White FJ and Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science, 221, 1054-1057.
84. Wiesel FA, Nordstrom AL, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology, 114, 31-38.
85. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB and Brodie D (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. American Journal of Psychiatry, 146, 905-908.
86. Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT and Wilson AA (1986) Positron emission tomography reveals elevated D2 DA receptors in drug-naive schizophrenics. Science, 234, 1558-1563.